标题
Nivolumab in NSCLC: latest evidence and clinical potential
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 7, Issue 2, Pages 85-96
出版商
SAGE Publications
发表日期
2015-01-22
DOI
10.1177/1758834014567470
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Silica-induced Chronic Inflammation Promotes Lung Carcinogenesis in the Context of an Immunosuppressive Microenvironment
- (2015) Javier Freire et al. NEOPLASIA
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
- (2014) R D Harvey CLINICAL PHARMACOLOGY & THERAPEUTICS
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
- (2014) S.S. Ramalingam et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Immunotherapy in the treatment of non-small cell lung cancer
- (2014) Raghav Sundar et al. LUNG CANCER
- Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
- (2014) Yang Zhang et al. OncoTargets and Therapy
- Antitumor immune responses induced by ionizing irradiation and further immune stimulation
- (2013) Benjamin Frey et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer
- (2013) Julie R. Brahmer JOURNAL OF CLINICAL ONCOLOGY
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- (2013) Silvia C. Formenti et al. JNCI-Journal of the National Cancer Institute
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?
- (2013) Julie R. Brahmer SEMINARS IN ONCOLOGY
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
- (2013) J. R. Brahmer et al. Cancer Immunology Research
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- (2012) Esdy N. Rozali et al. Clinical & Developmental Immunology
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
- (2012) G. R. Oxnard et al. JNCI-Journal of the National Cancer Institute
- Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
- (2012) Leow Pay Chin et al. Journal of Thoracic Oncology
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
- (2010) Benjamin Solomon et al. Journal of Thoracic Oncology
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- (2010) Kaan Harmankaya et al. MEDICAL ONCOLOGY
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
- (2009) O Akbari et al. Mucosal Immunology
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
- (2008) Lei Zhang et al. CLINICAL IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started